NO771860L - P}visning av kreft. - Google Patents
P}visning av kreft.Info
- Publication number
- NO771860L NO771860L NO771860A NO771860A NO771860L NO 771860 L NO771860 L NO 771860L NO 771860 A NO771860 A NO 771860A NO 771860 A NO771860 A NO 771860A NO 771860 L NO771860 L NO 771860L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- tumor
- malignant melanoma
- extract
- patients
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 65
- 201000011510 cancer Diseases 0.000 title claims description 22
- 201000001441 melanoma Diseases 0.000 claims description 56
- 239000000284 extract Substances 0.000 claims description 51
- 210000000265 leukocyte Anatomy 0.000 claims description 49
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 19
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001531 bladder carcinoma Diseases 0.000 claims description 3
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000011767 Sarcoma of cervix uteri Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 15
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000005112 urinary bladder cancer Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 4
- 230000008260 defense mechanism Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000032972 Conjunctival malignant melanoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001674788 Pasites Species 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69045476A | 1976-05-27 | 1976-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO771860L true NO771860L (no) | 1977-11-29 |
Family
ID=24772522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO771860A NO771860L (no) | 1976-05-27 | 1977-05-26 | P}visning av kreft. |
Country Status (18)
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3999944A (en) * | 1975-02-28 | 1976-12-28 | Hoffmann-La Roche Inc. | Detection of breast cancer |
| US4043757A (en) * | 1975-05-20 | 1977-08-23 | Ortho Pharmaceutical Corporation | Method for detection of human mammary carcinoma |
-
1977
- 1977-05-20 AU AU25341/77A patent/AU506539B2/en not_active Expired
- 1977-05-20 ZA ZA00773026A patent/ZA773026B/xx unknown
- 1977-05-20 IL IL52133A patent/IL52133A0/xx unknown
- 1977-05-20 NZ NZ184159A patent/NZ184159A/xx unknown
- 1977-05-24 IE IE1055/77A patent/IE45284B1/en unknown
- 1977-05-24 FI FI771646A patent/FI771646A7/fi not_active Application Discontinuation
- 1977-05-25 JP JP6000577A patent/JPS52145517A/ja active Pending
- 1977-05-25 LU LU77413A patent/LU77413A1/xx unknown
- 1977-05-25 FR FR7715965A patent/FR2352533A1/fr active Granted
- 1977-05-26 NO NO771860A patent/NO771860L/no unknown
- 1977-05-26 BE BE177925A patent/BE855063A/xx unknown
- 1977-05-26 DK DK233277A patent/DK233277A/da not_active Application Discontinuation
- 1977-05-26 ES ES459164A patent/ES459164A1/es not_active Expired
- 1977-05-26 AT AT376977A patent/AT357690B/de not_active IP Right Cessation
- 1977-05-26 GB GB22283/77A patent/GB1520208A/en not_active Expired
- 1977-05-26 SE SE7706203A patent/SE7706203L/ not_active Application Discontinuation
- 1977-05-27 NL NL7705873A patent/NL7705873A/xx not_active Application Discontinuation
- 1977-05-27 DE DE19772724114 patent/DE2724114A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL52133A0 (en) | 1977-07-31 |
| SE7706203L (sv) | 1977-11-28 |
| DE2724114A1 (de) | 1977-12-15 |
| FI771646A7 (enrdf_load_stackoverflow) | 1977-11-28 |
| LU77413A1 (enrdf_load_stackoverflow) | 1978-06-26 |
| AT357690B (de) | 1980-07-25 |
| JPS52145517A (en) | 1977-12-03 |
| BE855063A (fr) | 1977-11-28 |
| ATA376977A (de) | 1979-12-15 |
| AU506539B2 (en) | 1980-01-10 |
| AU2534177A (en) | 1978-11-23 |
| ES459164A1 (es) | 1978-04-16 |
| IE45284L (en) | 1977-11-27 |
| GB1520208A (en) | 1978-08-02 |
| DK233277A (da) | 1977-11-28 |
| FR2352533B1 (enrdf_load_stackoverflow) | 1980-06-13 |
| FR2352533A1 (fr) | 1977-12-23 |
| ZA773026B (en) | 1978-04-26 |
| NZ184159A (en) | 1979-03-28 |
| NL7705873A (nl) | 1977-11-29 |
| IE45284B1 (en) | 1982-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grosser et al. | Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes | |
| Weller et al. | Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. | |
| Porter et al. | Prevalence of antibodies to EB virus and other herpesviruses | |
| McCoy et al. | Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human malignant melanoma | |
| US3999944A (en) | Detection of breast cancer | |
| BJÖRKLUND | Tissue Polypeptide Antigen (TТРА): Biology, Biochemistry, Improved Assay Methodology, Clinical Significance in Cancer and Other Conditions | |
| Zone et al. | Circulating immune complexes of IgA type in dermatitis herpetiformis | |
| CA1045031A (en) | Serological test for gonorrheal antibodies | |
| Hollinshead et al. | Reactivity between herpesvirus type 2-related soluble cervical tumor cell membrane antigens and matched cancer and control sera | |
| Mohos et al. | Insulin-induced glomerulosclerosis in the rabbit | |
| Friedman et al. | A hemagglutination test for detection of adenovirus antibodies | |
| Poskitt et al. | RENAL DEPOSITION OF SOLUBLE IMMUNE COMPLEXES IN MICE BEARING B-16 MELANOMA: Characterization of Complexes and Relationship to Tumor Progress | |
| Habel et al. | Immunological evidence on the role of the lymphocyte in antibody formation | |
| CN108948185B (zh) | 蒜氨酸抗原及其免疫应答获得的家兔蒜氨酸抗体 | |
| Badger et al. | Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids | |
| Braathen et al. | Evidence for Fc IgG receptors and complement factor C3b receptors in human choroid plexus | |
| Elias et al. | Cellular immunity in patients with colorectal adenocarcinoma measured by autologous leukocyte migration inhibition | |
| Goodwin et al. | Immune responses induced by human malignant melanoma in the rabbit | |
| Pondman et al. | The specificity of the complement antiglobulin test | |
| Sheikh et al. | Malignant glial neoplasms: definition of a humoral host response to tumor-associated antigen (s) | |
| NO771860L (no) | P}visning av kreft. | |
| Schultz et al. | Glomerular disease in two patients with urticaria-cutaneous vasculitis and hypocomplementemia | |
| Ilfeld et al. | IgG monoclonal gammopathy in four patients with polymyalgia rheumatica | |
| Svec | Immunologic and clinical observations of granulocyte‐specific antinuclear antibodies | |
| Walters et al. | Specific cell‐mediated immunity in the laboratory diagnosis of dermatophytic infections |